Clinical Trial Update: Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating concurrent chemotherapy with intensity-modulated radiotherapy for intermediate-risk nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: COMPLETED